Glycoengineered low fucose FcαRI BsAbs increased tumor cell killing via NK cells. (A + B) ADCC of A431 by NK cells in the presence of glycovariants FcαRI BsAbs 0.1 or 1.0 µg/ml for 4 and 24 h. ADCC was normalized to No Ab treatment. (C + D) ADCC of MC38-cEGFR by NK cells in the presence of glycovariants FcαRI BsAbs 0.1 or 1.0 µg/ml for 4 and 24 h. Data is presented as mean ± standard deviations (SD); n = 3 per group (*P < 0.05). Two-way ANOVA with Tukey’s multiple-comparison correction was performed. Representative experiments out of 3 independent experiments are shown.